Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-25012 Injection Receives Clinical Trial Approval Notice

Shenyang Xingqi Pharmaceutical (300573.SZ) announced that recently, the company received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for SQ-25012 Injection, agreeing to conduct clinical trials of this product for the proposed treatment of thyroid eye disease. SQ-25012 Injection is a recombinant humanized IgG1-type trispecific antibody, a Class 1 innovative therapeutic biologic developed by the company, and is proposed clinically for the treatment of thyroid eye disease. In accordance with the relevant requirements for Class 1 innovative therapeutic biologic injections, the company has completed pharmaceutical and non-clinical pharmacological and toxicological studies of SQ-25012 Injection, among other aspects. The study results indicate that SQ-25012 Injection has good safety and clinical development value.